In contrast, of the 41 HER2-overexpressing NSCLC patients treated with 5.4 mg/kg of T-DXd (cohort 1A), only 7.3% were found to have pneumonitis, with 4.9% grade 3 or higher events, including two deaths. Here, ERBB2 is linked to non-small cell lung carcinoma.